The license-giving program is the Indian government's way of making lifesaving drugs affordable to its people. Nexavar's $69,000 price tag is 41 times the per capita income in India, Forbes points out. The drugs the government committee is now considering for licensing include those for HIV and diabetes, which affect tens of millions of Indians. (Previously, the government committee only looked at cancer drugs, so the addition of these common diseases are a first, Bloomberg reports.)